

Please note that this is not an enrollment form. To download our forms, visit [diplomat.is/rxforms](http://diplomat.is/rxforms).

Drug	Indications <sup>1</sup>					Route	Manufacturer
	Ankylosing Spondylitis	Giant Cell Arteritis	Juvenile Idiopathic Arthritis	Psoriatic Arthritis	Rheumatoid Arthritis		
<b>Actemra®</b> (tocilizumab) <i>For patients ages 2+</i>		▪	▪		▪	Intravenous, Subcutaneous	Genentech
<b>Cimzia®</b> (certolizumab)	▪			▪	▪	Subcutaneous	UCB
<b>Cosentyx®</b> (secukinumab)	▪			▪		Subcutaneous	Novartis
<b>Enbrel®</b> (etanercept) <i>For patients ages 2+</i>	▪		▪	▪	▪	Subcutaneous	Amgen
<b>Humira®</b> (adalimumab) <i>For patients ages 2+</i>	▪		▪	▪	▪	Subcutaneous	Abbvie
<b>Kevzara®</b> (sarilumab)					▪	Subcutaneous	Regeneron / Sanofi
<b>Orencia®</b> (abatacept)			▪ <i>IV: ages 6+ SC: ages 2+</i>	▪	▪	Intravenous, Subcutaneous	Bristol-Myers Squibb
<b>Otezla®</b> (apremilast)				▪		Oral	Celgene
<b>Simponi®</b> (golimumab)	▪			▪	▪	Subcutaneous	Janssen
<b>Simponi Aria®</b> (golimumab)					▪	Intravenous	Janssen
<b>Stelara®</b> (ustekinumab)				▪		Subcutaneous	Janssen
<b>Xeljanz® / Xeljanz® XR</b> (tofacitinib)					▪	Oral	Pfizer

<sup>1</sup>Medications listed are prescribed for adults, unless otherwise indicated.